Company News 

Big pharma braced for big changes in 2018

Big pharma braced for big changes in 2018

The 2018 JPMorgan Healthcare Conference – the biggest global meeting of pharmaceutical professionals – has kicked off in much the same way as most of the recent conferences have done: with an acquisition. US biotechnology giant Celgene has pledged to pay up to $6.9bn (£5.1bn) for an early-stage drug maker called Impact Bioscience, if its clinical trials are successful.

To continue reading, subscribe today

and enjoy unlimited access to the following:

  • Tips of the Week
  • Funds coverage
  • Weekly features on big investment themes
  • Trading ideas
  • Comprehensive companies coverage
  • Economic analysis
Subscribe to Investors Chronicle

Related topics

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now